Scarica l'app Stockscreener
104.80
1.05%
-1.11
Dopo l'orario di chiusura:
104.80
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NUVL Giù?
Forum
Previsione
Precedente Chiudi:
$105.91
Aprire:
$106.37
Volume 24 ore:
524.24K
Relative Volume:
0.90
Capitalizzazione di mercato:
$8.14B
Reddito:
-
Utile/perdita netta:
$-224.29M
Rapporto P/E:
-26.87
EPS:
-3.9
Flusso di cassa netto:
$-185.06M
1 W Prestazione:
-4.38%
1M Prestazione:
+8.01%
6M Prestazione:
+34.51%
1 anno Prestazione:
+20.71%
Intervallo 1D:
$103.52
$107.49
Intervallo di 1 settimana:
$103.52
$111.94
Portata 52W:
$55.53
$112.88
Nuvalent Inc Stock (NUVL) Company Profile
Nome
Nuvalent Inc
Settore
Industria
Telefono
508-446-2272
Indirizzo
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Confronta NUVL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
104.80 | 8.22B | 0 | -224.29M | -185.06M | -3.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-11-12 | Iniziato | Canaccord Genuity | Buy |
| 2025-10-16 | Ripresa | Stifel | Buy |
| 2025-10-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-09-04 | Ripresa | Guggenheim | Buy |
| 2025-09-03 | Iniziato | Raymond James | Outperform |
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2025-03-14 | Aggiornamento | UBS | Neutral → Buy |
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-10-24 | Iniziato | UBS | Neutral |
| 2024-08-29 | Iniziato | Barclays | Overweight |
| 2024-04-17 | Iniziato | Jefferies | Buy |
| 2024-04-01 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-02-28 | Ripresa | Guggenheim | Buy |
| 2024-02-23 | Iniziato | Robert W. Baird | Outperform |
| 2023-09-27 | Iniziato | Stifel | Buy |
| 2023-08-08 | Iniziato | SVB Securities | Market Perform |
| 2023-07-24 | Iniziato | Guggenheim | Buy |
| 2023-01-18 | Iniziato | Wedbush | Outperform |
| 2022-06-24 | Iniziato | BMO Capital Markets | Outperform |
Mostra tutto
Nuvalent Inc Borsa (NUVL) Ultime notizie
Nuvalent announces public offering of common stock - MSN
Nuvalent, Inc. $NUVL Shares Acquired by Braidwell LP - MarketBeat
Is Nuvalent Inc stock a defensive play in 2025Trade Analysis Summary & Expert Curated Trade Setup Alerts - moha.gov.vn
Natixis Makes New $1.75 Million Investment in Nuvalent, Inc. $NUVL - MarketBeat
Insider Selling: Nuvalent (NASDAQ:NUVL) CFO Sells 7,084 Shares of Stock - MarketBeat
HighVista Strategies LLC Has $3.85 Million Stake in Nuvalent, Inc. $NUVL - MarketBeat
Nuvalent appoints Ron Squarer to board of directors By Investing.com - Investing.com Nigeria
Trading the Move, Not the Narrative: (NUVL) Edition - news.stocktradersdaily.com
Insider Sell Alert: Alexandra Balcom Sells Shares of Nuvalent In - GuruFocus
Nuvalent appoints Ron Squarer to board of directors - Investing.com
Nuvalent Insider Sold Shares Worth $781,537, According to a Recent SEC Filing - marketscreener.com
Ron Squarer Joins Nuvalent Board as Independent Director - TipRanks
Nuvalent Appoints Ron Squarer to Board of Directors - Finviz
Nuvalent, Inc. Announces Board Changes - marketscreener.com
Nuvalent (Nasdaq: NUVL) taps Ron Squarer for board as zidesamtinib launch prep builds - Stock Titan
Nuvalent, Inc. (NUVL) is a buy on lung cancer treatment prospects - MSN
Nuvalent (NUVL) Valuation After FDA Breakthrough Designation and Investor Optimism in Lung Cancer Franchise - Sahm
Nuvalent, Inc. $NUVL Shares Acquired by Walleye Capital LLC - MarketBeat
Stempoint Capital LP Has $4.57 Million Stake in Nuvalent, Inc. $NUVL - MarketBeat
Nuvalent’s Clinical and Financial Momentum Captivates Investors - AD HOC NEWS
Nuvalent, Inc. (NUVL) is a Buy On lung Cancer Treatment Prospects - Insider Monkey
Norges Bank Buys Shares of 374,597 Nuvalent, Inc. $NUVL - MarketBeat
Nuvalent, Inc. (NASDAQ:NUVL) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Nuvalent (NUVL) Price Target Increased by 11.46% to 142.80 - Nasdaq
Affinity Asset Advisors LLC Reduces Position in Nuvalent, Inc. $NUVL - MarketBeat
Russell Investments Group Ltd. Sells 28,747 Shares of Nuvalent, Inc. $NUVL - MarketBeat
Rhumbline Advisers Has $5.04 Million Stock Holdings in Nuvalent, Inc. $NUVL - MarketBeat
Layoff Watch: Is Nuvalent Inc stock trading at a premium valuationEarnings Growth Summary & Free Expert Verified Stock Movement Alerts - BỘ NỘI VỤ
NUVL: Late-stage oncology assets show strong efficacy and safety, with first approvals targeted for 2026 - TradingView
Will Nuvalent Inc. stock attract more institutional investorsMarket Sentiment Summary & Long-Term Safe Investment Ideas - Newser
Nuvalent Insider Sold Shares Worth $434,319, According to a Recent SEC Filing - marketscreener.com
Nuvalent Chief Development Officer Sells Shares - TradingView
Officer Noci Sells 4,000 ($434.3K) Of Nuvalent Inc [NUVL] - TradingView
Nuvalent (NUVL) Stock Analysis Report | Financials & Insights - Benzinga
American Century Companies Inc. Boosts Holdings in Nuvalent, Inc. $NUVL - MarketBeat
Creative Planning Buys 9,079 Shares of Nuvalent, Inc. $NUVL - MarketBeat
(NUVL) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Returns Recap: Is Nuvalent Inc. stock trading near support levelsJuly 2025 Volume & Long Hold Capital Preservation Tips - BỘ NỘI VỤ
Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference - Eastern Progress
Nuvalent (NASDAQ:NUVL) Director Sells $639,814.50 in Stock - MarketBeat
Does Nuvalent’s Recent Trial Success Justify the Stock’s 36% 2025 Rally? - Yahoo Finance
Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results (PR Newswire) - Aktiellt
Nuvalent Director and 10% Owner Matthew Shair Sells 7,500 Shares - TradingView
Nuvalent to Participate in the Piper Sandler 37th Annual Healthc - GuruFocus
Universal Beteiligungs und Servicegesellschaft mbH Sells 14,688 Shares of Nuvalent, Inc. $NUVL - MarketBeat
Nuvalent: Deerfield funds sell $70.8m in NUVL stock By Investing.com - Investing.com South Africa
Nuvalent (NUVL) Receives a New Rating from Truist Financial - The Globe and Mail
Nuvalent closes $500 million public offering of common stock By Investing.com - Investing.com India
Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling Stockholders - Finviz
Nuvalent: Deerfield funds sell $70.8m in NUVL stock - Investing.com
Nuvalent Announces Closing of Public Offering of Common Stock an - GuruFocus
Nuvalent Inc Azioni (NUVL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):